ACR246 / Adcoris - LARVOL DELTA

ACR246, a first in next-generation 5T4-ADC, as a potential choice of treating 5T4-positive solid tumors. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Oncology • Solid Tumor • TPBG

A dose escalation and cohort expansion phase I/IIa study of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT06238401 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P1/2 data • Oncology • Solid Tumor

ACR246-101: An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=77 | Recruiting | Sponsor: Hangzhou Adcoris Biopharmacy Co., Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2024 ➔ Oct 2024 | Trial primary completion date: Jan 2025 ➔ Jun 2025

Enrollment open • Metastases • Trial initiation date • Trial primary completion date • Oncology • Solid Tumor

Phase I dose escalation trial to evaluate safety and preliminary efficacy of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors (ESMO 2024) - P1 | "Previously, several 5T4-ADCs were developed and advanced to phase 1 clinical trials, including PF-06263507, ASN004 and SYD1875. Dose limiting toxicity (DLT) will be assessed at each dose level. The DLT evaluation period will be 21 days."

Clinical • Metastases • P1 data • Oncology • Solid Tumor • TPBG

Preclinical studies of an innovative 5T4-ADC ACR246 with the potential to better treat 5T4-positive solid tumors. (ASCO 2024) - "The overall preclinical profile marks ACR246 has the potential to become the best in class (BIC) 5T4-ADC, showing more favorable benefit-risk ratio in clinic."

Preclinical • Oncology • Solid Tumor • CXCL12 • TPBG

Study of ACR246 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=77 | Not yet recruiting | Sponsor: Hangzhou Adcoris Biopharmacy Co., Ltd

New P1 trial • Oncology • Solid Tumor